top of page

How a new CEO has been trying to position Editas to execute on the promise of CRISPR

Gilmore O’Neill is working to inject stability and focus at Editas as the company aims to execute on both ex-vivo and in-vivo crispr gene therapies.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page